Piramal Pharma releases its Sustainability Report for FY 2023-24 under the theme, 'Building Resilience for a Sustainable Tomorrow'

Nandini Piramal, Chairperson of Piramal Pharma Ltd., said, "As we advance on our sustainability journey, we are deeply committed to transparency, accountability, and continuous improvement in our business practices. Our latest Sustainability Report not only highlights the milestones we've achieved but also demonstrates our capability to adapt to evolving global standards. By revising our Scope 1 and 2 GHG emissions and energy consumption for FY 2023, we have significantly improved data accuracy, enabling us to assess and manage our environmental footprint. Looking ahead, we remain committed to driving sustainable growth; reinforcing our core purpose of 'Doing Well and Doing Good,' while strengthening our focus on making meaningful, measurable progress toward a more sustainable future."

Key Highlights of the Report:

Responsible Operation

Business Resilience

Quality & Excellence

Customer Centricity

The Sustainability report follows GRI standards and is aligned with SASSB and UNGC frameworks, underscoring PPL's commitment to sustainable growth, responsible capital allocation, and impactful stakeholder engagement. For more information, please refer to the full report available at https://www.piramalpharma.com/sustainability.

About Piramal Pharma Ltd:

Piramal Pharma Limited (PPL, NSE: PPLPHARMA I BSE: 543635), offers a portfolio of differentiated products and services through its 17* global development and manufacturing facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing organization; Piramal Critical Care (PCC), a complex hospital generics business; and the India Consumer Healthcare business, selling over-the-counter consumer and wellness products. In addition, one of PPL's associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market. Further, PPL has a strategic minority investment in Yapan Bio Private Limited, that operates in the biologics / bio-therapeutics and vaccine segments. In October 2020, PPL received a 20% strategic growth investment from the Carlyle Group.

For more information visit: Piramal Pharma | LinkedIn

*Includes one facility through minority investment in Yapan Bio

View original content:https://www.prnewswire.co.uk/news-releases/piramal-pharma-releases-its-sustainability-report-for-fy-2023-24-under-the-theme-building-resilience-for-a-sustainable-tomorrow-302267649.html